Generic Drugs: The Same, But Not

(The Atlantic) – But pharmaceutical firms were not the only entities with economic interests in the similarity and dissimilarity of generic drugs. As many physicians’ organizations began to argue, policymakers and insurance companies who supported generic substitution could also be accused of having an equal and opposite economic interest: the incentive to spend less money whether the quality of care was the same or not. These two mutually suspicious positions, pro-generic and anti-generic, hardened into fairly stable ideologies by the close of the 20th century.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.